Pharmacogenetics: the outlook for genetic testing in statin therapy
Daniel I Chasman* and Paul M Ridker
Correspondence
*
Brigham and Women's Hospital and Harvard Medical School,
900 Commonwealth Avenue, East Boston,
MA
02215,
USA
Email dchasman@rics.bwh.harvard.edu
Why do some patients require an altered statin dose to achieve target cholesterol levels? In this month's Viewpoint article, understanding the genetic factors involved in statin therapy, and whether they could be used to limit the variation in patient response is discussed by Daniel Chasman and Paul Ridker.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
